Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences

Vaccine

Volumn 28, Issue 36, 2010, Pages 5774-5784

  Gravel, Caroline ^a   Li, Changgui ^b   Wang, Junzhi ^b   Hashem, Anwar M ^a,d   Jaentschke, Bozena ^a   Xu, Kang wei ^b   Lorbetskie, Barry ^a   Gingras, Genevieve ^a   Aubin, Yves ^a   Van Domselaar, Garry ^c   Girard, Michel ^a   He, Runtao ^c   Li, Xuguang ^a,d  

^a HEALTH CANADA   (Canada)

^b NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^c PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Neuraminidase; Universal epitope; Vaccine

Indexed keywords

INFLUENZA VACCINE; VIRUS SIALIDASE;

ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CROSS REACTION; ENZYME ACTIVITY; ENZYME SPECIFICITY; INFLUENZA VIRUS A; INFLUENZA VIRUS B; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ALIGNMENT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CONSERVED SEQUENCE; CROSS REACTIONS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; NEURAMINIDASE; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 77955553259     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.075     Document Type: Article

References (54)

1. Webster R.G., Bean W.J. Genetics of influenza virus. Annu Rev Genet 1978, 12:415-431.
2. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000 2000, 69:531-569.
3. Air G.M., Laver W.G. The neuraminidase of influenza virus. Proteins 1989, 6:341-356.
4. Kilbourne E.D., Laver W.G., Schulman J.L., Webster R.G. Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol 1968, 2:281-288.
5. Compans R.W., Dimmock N.J., Meier-Ewert H. Effect of antibody to neuraminidase on the maturation and hemagglutinating activity of an influenza A2 virus. J Virol 1969, 4:528-534.
6. Liu C., Eichelberger M.C., Compans R.W., Air G.M. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol 1995, 69:1099-1106.
7. Palese P., Compans R.W. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 1976, 33:159-163.
8. Hashem A.M., Flaman A.S., Farnsworth A., Brown E.G., Van Domselaar G., He R., et al. Aurintricarboxylic acid is a potent inhibitor of influenza A and B virus neuraminidases. PLoS One 2009, 4:e8350.
9. Ohuchi M., Asaoka N., Sakai T., Ohuchi R. Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect 2006, 8:1287-1293.
10. Su B., Wurtzer S., Rameix-Welti M.A., Dwyer D., van der Werf S., Naffakh N., et al. Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA). PLoS One 2009, 4(12):e8495.
11. Wood J.M., Dunleavy U., Newman R.W., Riley A.M., Robertson J.S., Minor P.D., et al. The influence of the host cell on standardisation of influenza vaccine potency. Dev Biol Stand 1999, 98:183-188.
12. Sylte M.J., Suarez D.L. Influenza neuraminidase as a vaccine antigen. Curr Top Microbiol Immunol 2009, 333:227-241.
13. Schulman J.L., Khakpour M., Kilbourne E.D. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 1968, 2:778-786.
14. Johansson B.E., Grajower B., Kilbourne E.D. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 1993, 11:1037-1039.
15. Rott R., Becht H., Orlich M. The significance of influenza virus neuraminidase in immunity. J Gen Virol 1974, 22:35-41.
16. Webster R.G., Laver W.G., Kilbourne E.D. Reactions of antibodies with surface antigens of influenza virus. J Gen Virol 1968, 3:315-326.
17. Sandbulte M.R., Jimenez G.S., Boon A.C., Smith L.R., Treanor J.J., Webby R.J. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007, 4:e59.
18. Takahashi Y., Hasegawa H., Hara Y., Ato M., Ninomiya A., Takagi H., et al. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice. J Infect Dis 2009, 199:1629-1637.
19. DiNapoli J.M., Nayak B., Yang L., Finneyfrock B.W., Cook A., Andersen H., et al. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J Virol 2010, 84:1489-1503.
20. Murphy B.R., Kasel J.A., Chanock R.M. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 1972, 286:1329-1332.
21. Couch R.B., Kasel J.A., Gerin J.L., Schulman J.L., Kilbourne E.D. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 1974, 129:411-420.
22. Kilbourne E.D., Couch R.B., Kasel J.A., Keitel W.A., Cate T.R., Quarles J.H., et al. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 1995, 13:1799-1803.
23. Beutner K.R., Chow T., Rubi E., Strussenberg J., Clement J., Ogra P.L. Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. J Infect Dis 1979, 140:844-850.
24. Ogra P.L., Chow T., Beutner K.R., Rubi E., Strussenberg J., DeMello S., et al. Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans. J Infect Dis 1977, 135:499-506.
25. Cate T.R., Rayford Y., Niño D., Winokur P., Brady R., Belshe R., et al. High dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010, 28:2076-2079.
26. Johansson B.E., Pokorny B.A., Tiso V.A. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition. Vaccine 2002, 20:1670-1674.
27. Brett I.C., Johansson B.E. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 2005, 339:273-280.
28. Gillim-Ross L., Subbarao K. Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses?. PLoS Med 2007, 4:e91.
29. Gerentes L., Kessler N., Aymard M. A sensitive and specific ELISA immunocapture assay for rapid quantitation of influenza A/H3N2 neuraminidase protein. J Virol Methods 1998, 73:185-195.
30. Gulati U., Wu W., Gulati S., Kumari K., Waner J.L., Air G.M. Mismatched hemagglutinin and neuraminidase specificities in recent human H3N2 influenza viruses. Virology 2005, 339:12-20.
31. Tanimoto T., Nakatsu R., Fuke I., Ishikawa T., Ishibashi M., Yamanishi K., et al. Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography. Vaccine 2005, 23:4598-4609.
32. Bright R.A., Neuzil K.M., Pervikov Y., Palkonyay L. WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14, 2008. Vaccine 2009, 27:6366-6369.
33. Bucher D.J., Li S.S.L., Kehoe J.M., Kilbourne E.D. Chromatographic isolation of the hemagglutinin polypeptides from influenza virus vaccine and determination of their amino-terminal sequences. Proc Nat Acad Sci U S A 1976, 73:238-242.
34. Calam D.H., Davidson J. Isolation of influenza viral proteins by size-exclusion and ion-exchange high-performance liquid chromatography: the influence of conditions on separation. J Chromatogr 1984, 296:285-292.
35. Phelan M.A., Cohen K.A. Gradient optimization principles in reversed-phase high-performance liquid chromatography and the separation of influenza virus components. J Chromatogr 1983, 266:55-66.
36. Kapteyn J.C., Saidi M.D., Dijkstra R., Kars C., Tjon J.C., Weverling G.J., et al. Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: a novel RP-HPLC method. Vaccine 2006, 24:3137-3144.
37. Garcia-Cañas V., Lorbetskie B., Girard M. Rapid and selective characterization of influenza virus constituents in monovalent and multivalent preparations using non-porous reversed-phase high performance liquid chromatography columns. J Chromatogr A 2006, 1123:225-232.
38. Kapteyn J.C., Porre A.M., de Rond E.J., Hessels W.B., Tijms M.A., Kessen H., et al. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 2009, 27:1468-1477.
39. García-Cañas V., Lorbetskie B., Bertrand D., Cyr T.D., Girard M. Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection. Anal Chem 2007, 79:3164-3172.
40. Williams T.L., Luna L., Guo Z., Cox N.J., Pirkle J.L., Donis R.O., et al. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 2008, 26:2510-2520.
41. Luna L.G., Williams T.L., Pirkle J.L., Barr J.R. Ultra performance liquid chromatography isotope dilution tandem mass spectrometry for the absolute quantification of proteins and peptides. Anal Chem 2008, 80:2688-2693.
42. Garcia-Cañas V., Lorbetskie B., Cyr T.D., Hefford M.A., Smith S., Girard M. Approach to the profiling and characterization of influenza vaccine constituents by the combined use of size-exclusion chromatography, gel electrophoresis and mass spectrometry. Biologicals 2010, 38:294-302.
43. Chun S., Li C., Van Domselaar G., Wang J., Farnsworth A., Cui X., et al. Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza A viral hemagglutinins. Vaccine 2008, 26:6068-6076.
44. Li K.B. ClustalW-MPI: ClustalW analysis using distributed and parallel computing. Bioinformatics 2003, 19:1585-1586.
45. Harvey R., Wheeler J.X., Wallis C.L., Robertson J.S., Engelhardt O.G. Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1). Vaccine 2008, 26:6550-6554.
46. Li C., Jaentschke B., Song Y., Wang J., Cyr T.D., Van Domselaar G., et al. A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide. Nat Protoc 2010, 5:14-19.
47. Buxton R.C., Edwards B., Juo R.R., Voyta J.C., Tisdale M., Bethell R.C. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Anal Biochem 2000, 280:291-300.
48. Deroo T., Jou W.M., Fiers W. Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine 1996, 14:561-569.
49. Blok J., Air G.M., Laver W.G., Ward C.W., Lilley G.G., Woods E.F., et al. Studies on the size, chemical composition, and partial sequence of the neuraminidase (NA) from type A influenza viruses show that the N-terminal region of the NA is not processed and serves to anchor the NA in the viral membrane. Virology 1982, 119:109-121.
50. Air G.M., Ritchie L.R., Laver W.G., Colman P.M. Gene and protein sequence of an influenza neuraminidase with hemagglutinin activity. Virology 1985, 145:117-122.
51. Shaw M.W., Lamb R.A., Erickson B.W., Briedis D.J., Choppin P.W. Complete nucleotide sequence of the neuraminidase gene of influenza B virus. Proc Natl Acad Sci U S A 1982, 79:6817-6821.
52. Li C., Shao M., Cui X., Song Y., Li J., Yuan L., et al. Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China. Biologicals 2010, 38:284-289.
53. Shannon C.E. The mathematical theory of communication. 1963. MD Comput. 1997, 14:306-317.
54. Colman P.M., Hoyne P.A., Lawrence M.C. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol 1993, 67:2972-2980.